Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus taxanes or vinorelbine in trastuzumab-pretreated HER2-positive metastatic breast cancer
ChiCTR2000041217Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib and vinorelbine in breast cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
pyrotinibvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000041217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041217.